Study on the Correlation between G211T Mutation and the Efficacy and Safety of Morphine Treatment on Cancer Pain

Abstract

Abstract: Objective To study the distribution frequency of UGT2B7 gene polymorphism in patients with cancer pain, and evaluate the effect of UGT2B7 * 1 G211T polymorphisms on the effect and safety of morphine. Methods Patients with moderate-severe cancer pain were treated with morphine,the numerical rating scale（NRS）was used for pain evaluation. Treatment data and adverse effects were recorded and UGT2B7 gene polymorphism was detected. According to the genotype and morphine dose, the impact of UGT2B7*1 G211T mutation on morphine analgesia efficacy and safety were evaluated. Results There were 68.60% patients with wild-type UGT2B7*1 G211G, 24.42% patients with heterozygous mutation UGT2B7*1 G211T and 6.98% patients with homozygous mutant UGT2B7*1 T211T in Chinese patients with cancer pain. UGT2B7*1 G211T mutation group (ie group GT+ group TT) needed higher doses of morphine than GG group（P <0.05）. Dizziness and grade 2~3 constipation happened more frequently in the UGT2B7*1 G211T mutation group (ie group GT+ group TT) than the wild-type group (group GG) ( P <0.05). Conclusion UGT2B7*1 G211T polymorphisms have impact on analgesic effect and safety of morphine.

Key words: cancer pain, morphine, UGT2B7, polymorphism

CLC Number:

R969

WU Nan, ZHANG Dong-lei, WANG Lei, DING Nian-yang, LI Jie YANG, Yang YAN, Dan TONG, Ben-ding, WEI Qing. Study on the Correlation between G211T Mutation and the Efficacy and Safety of Morphine Treatment on Cancer Pain[J]. Chinese Journal of Pharmacovigilance, 2017, 14(1): 14-18.

References

[1] Treede R D,Rief W, Barke A,et al. A classification of chronic pain for ICD-11[J]. Pain, 2015, 156(6):1003-1007.
[2] 王雅杰, 王宁. 重视吗啡治疗癌痛病人的个体差异[J]. 药学服务与研究, 2010, 10(2):81-84.
[3] Hirota T, Ieiri I, Takane H, et al. Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy[J]. Drug Metab Dispos, 2003, 31(5): 677-680.
[4] Handal M, Grung M, Skurtveit S, et al. Pharmacokinetic diffrences of morphine and morphine-glucuronides are reflected in locomotor activity[J]. Pharmacol Biochem Behav, 2002, 73(4):883-892.
[5] Anderson G, Christrup L L, Sjogren P, et al. Changing M3G/M6G ratios and pharmacodynamics in a cancer patient during long-term morphine treatment[J]. J Pain Symptom Manag, 2002, 23(2):161-164.
[6] Coffman B L, Kearney W R, Green M D, et al. Analysis of opioid binding to UDP-glucuronosyltransferase 2B7 fusion proteins using nuclear magnetic resonance spectroscopy[J]. Mol Pharmacol, 2001, 59(6):1464-1469.
[7] NCCN. clinical practice guidelines in Oncology:Adult Cancer Pain（Version2.2013）[EB/OL].(2013-05-29)[2016-12-23]. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
[8] Klepstad P, Fladvad T, Skorpen F, et al. Influence from genetic variability on opioid use for cancer pain: A European genetic association study of 2294 cancer pain patients[J]. PAIN, 2011, 152(5):1139-1145.
[9] Fallon M, Reale C, Davies A, et al. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study[J]. J Support Oncol. 2011, 9(6):224-231.
[10] U.S.Department of health and human services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events [EB/OL]. (2009-05-28)[2016-12-23]. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.
[11] 易娟, 谢海棠, 周宏灏. UGT1A9 C2152T和UGT2B7 G211T突变在中国汉族人群中的分布[J]. 中国临床药理学与治疗学, 2007, 12(4):460-464.
[12] 许景峰, 赵刚涛, 许茜, 等. 焦磷酸测序技术检测UGT1A3 和UGT2B7在中国汉族人群中的基因多态性[J]. 中南药学, 2011, 9(10):728-733.
[13] Tian J N, Ho I K, Tsou H H, et al. UGT2B7 genetic polymorphisms are associated with the withdrawal symptoms in methadone maintenance patients[J]. Pharmacogenomics, 2012, 13(8): 879-888.
[14] Pasternak G W. The pharmacology of mu analgesics: from patients to genes[J]. Nuroscientist, 2001, 7(3):220-231.
[15] De Gregori S, De Gregori M, Ranzani G N, et al. Morphine matebolism, transport and brain disposition[J]. Metab Brain Dis, 2012, 27(1):1-5.
[16] Osborne R, Joel S, Trew D, et al. The analgesic activity of morphine -6-glucuronide[J]. Lancet, 1988, 1(8589):828.
[17] Joanne D, Joy R, Sophy G, et al. Constipation in cancer patients on morphine[J]. Support Care Cancer, 2008, 16(5):453-459.
[18] Cepeda M S, Farrar J T, Baumgarten M, et al. Side effects of opioids during short-term administration: effect of age, gender, and race[J]. Clin Pharmacol Ther, 2003, 74(2):102-112.
[19] Raffaeli W, Marconi G, Fanelli G, et al. Opioid-related side- effects after intrathecal morphine: A prospective, randomized, double-blind dose-response study[J]. Eur J Anaesthesiol, 2006, 23(7):605-610.
[20] Holer P. Treatment of opioid-induced gut dysfunction[J]. Expert Opin investig Drugs, 2007, 16(2):181-194.
[21] 刘欣煜,薛钧,朱婷,等. 硫酸吗啡缓释片、盐酸羟考酮缓释片与芬太尼透皮贴剂治疗癌痛引起便秘的风险比较[J]. 中国药房, 2015, 26(3):316-318.